Using a Federated Network of Real-World Data to Optimize Clinical Trials Operations
Clinical data shows semaglutide achieves HbA1c reductions of up to 1.7%2.0%, with weight loss exceeding 10% body mass in nearly 45%61% of patients, significantly outperforming earlier therapies
Please download one of our supported browsers
At 2.5mg/ml, a 0.25mg dose requires drawing just 0.1ml (10 units on an insulin syringe)
Ipamorelin does not touch cortisol and prolactin levels like GHRP-6
Methods This retrospective, database study used Optums de-identified Clinformatics Data Mart Database to identify glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment-nave adult patients with type 2 diabetes (T2D) initiating semaglutide QW, dulaglutide, liraglutide, or exenatide QW between January 1, 2018 and April 30, 2019